More dates

Webinar: Extreme Sensitivity in Those Affected by Chronic Neurodegenerative & Autoimmune Disorders

This event has passed Get tickets

Event description

Where: Online

CPE: 1.5 CPE points

Webinar Recording: Registering for this live event will also give you access to the webinar recording. 

Webinar recordings can be watched at any time.

Extreme Sensitivity in Those Affected by Chronic Neurodegenerative & Autoimmune Disorders 

Patients diagnosed with chronic disorders have often been misdiagnosed or undiagnosed for many years. This can create cell sensitivity that manifests as aggravation, reactions or herxing with standard prescribing.

Here we explore ways to identify sensitive patients and strategies for prescribing without causing aggravation.


Presenter: John Coleman

John Coleman is one of Australia’s most experienced naturopaths.

Beyond general naturopathy, he has a special focus on treating and educating about Neurodegenerative disorders, Lyme disease and other chronic disorders. He utilises a variety of strategies to assist patients regain their health and regularly works closely with integrative doctors.

He has presented at international conferences, workshopped with practitioners in 5 countries, was co-founder of Very Special Kids (a family support foundation) and founder of the Neuro Recovery Foundation. John is the author of “Rethinking Parkinson’s Disease” and “Shaky Past” (his autobiography).


Powered by

Tickets for good, not greed Humanitix donates 100% of profits from booking fees to charity




Refund policy

Please be advised that cancellations made up to one month before a scheduled event will be processed without a penalty. Cancellations made 2-4 weeks prior to a schedule event will be subject to a charge of 50% of the original ticket cost. Cancellations made 2 weeks or less prior to a scheduled event will not be entitled to any refund. However a full refund will be available to members for any events that have been cancelled or any future events that maybe cancelled due to COVID-19.